Applicability of cost-effectiveness analysis to management of chronic hepatitis B.
Dan
Yock Young
YY
Lim
Seng Gee
SG
D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use; D001208:Asia / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D006512:Hepatitis B Core Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000191:economics* / Q000627:therapeutic use; D019259:Lamivudine / Q000191:economics* / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000191:economics* / Q000627:therapeutic use; D011994:Recombinant Proteins
D000998:Antiviral Agents; D006512:Hepatitis B Core Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D019259:Lamivudine; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a